Profusa Builds NVIDIA-Powered AI Portal for Continuous Biomarker Monitoring
Company expects early 2026 rollout in EEA; doctor portal combines Lumee oxygen monitoring with NVIDIA NeMo to ship AI-driven medical workflows Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a industrial stage digital well being firm pioneering a next-generation expertise platform enabling the continual monitoring of a person’s biochemistry, publicizes the adoption of NVIDIA expertise…
